At the news
? NEUTRALIMPACT 4/10 8-K filed Jun 23, 2026 at 16:01 ET
FMC entered Amendment No. 7 to its credit agreement to facilitate a $200M supply and license deal with Corteva Agriscience for the Rimisoxafen molecule. The amendment permits Corteva to take a first-priority lien on the related IP and releases that IP from the lenders' collateral pool, with a contingent refund obligation of up to $200M if milestones are not met. This is a routine credit-agreement amendment enabling a non-core asset monetization, no new debt is created, and the existing credit facility terms remain unchanged.
- FMC will receive a $200M upfront payment from Corteva for a license to Rimisoxafen-related IP.
- The payment is subject to a contingent refund obligation of up to $200M if certain milestones are not achieved.
- Corteva will receive a first-priority security interest in the Rimi IP to secure the refund obligation.
- The credit agreement amendment releases the Rimi IP from the lenders' collateral pool and permits the Corteva lien.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access